Safe Administration of Medicines Question Answers 2022

Running Head: SAM
0
Safe Administration of Medicines
Question answers
student
8/27/2019

SAM
1
Table of Contents
Ans. 1...........................................................................................................................................................2
Ans. 2.......................................................................................................................................................2
Ans. 3.......................................................................................................................................................3
Ans. 4.......................................................................................................................................................3
Ans. 5.......................................................................................................................................................4
Ans. 6.......................................................................................................................................................4
Ans. 7.......................................................................................................................................................5
Ans. 8.......................................................................................................................................................7
Ans. 9.....................................................................................................................................................10
References.................................................................................................................................................12

SAM
2
Ans. 1
(A, B)
1. Pre-market assessment; this helps in evaluating and assessing the risks associated with
the therapeutic products (Ghosh, Skinner & Ferguson, 2006).
2. Post-market monitoring and enforcement of standards; this helps in identifying and
assessing any risk posed by the product after released in the market (Kumari, et al., 2016).
3. Licensing of Australian manufacturers and verifying overseas manufacturers'
compliance with the same standards (Kulkarni, 2017) as their Australian counterparts; this
helps in the manufacturing of risk free and good quality products by approving the selected
companies only (Department of Health: Therapeutic Goods administration, 2019).
Ans. 2
Phase 1: This particular phase is conducted to define effects of the medicine or medical device
on human involving how it is absorbed, metabolized, and eliminated from the body (Friedman et
al., 2015).
Phase 2: This 2nd phase of drug testing includes up to several 100 patients. This permits
researchers to deliver the pharmaceutical organization and the FDA with relative information
about the comparative safety and efficiency of the novel drug (Pallmann et al., 2018).
Phase 3: This is the large-scale examination, which delivers the knowledge of the efficiency of
the medicine or device, the advantages and the variety of probable side effects (Piantadosi,
2017).

SAM
3
Phase 4: The Pharmaceutical organizations can compare a new drug with other different drugs
already available in the market; to screen a drug's lasting efficiency and effects on a diseased
person’s quality of life; and to identify the cost-effectiveness of the drug therapy comparative to
other customary and new treatments (Wright, 2017).
Ans. 3
Pharmacokinetics is presently described as the study of the time taken by the drug for absorption,
circulation, metabolism, and elimination (Wagner, 2018). The Clinical pharmacokinetics is the
use of principles of pharmacokinetic to the harmless and effective therapeutic controlling of
drugs in a particular patient. Primary goals of medical pharmacokinetics comprise increasing
efficacy and reducing toxicity of drug therapy (Sime et al., 2018).
Pharmacodynamics defined as the association between concentration of the drug at the place of
action and the subsequent effect, counting the time course and concentration of therapeutic and
negative reaction (Kamath, 2016). The impacts of a drug existing at the location of action are
identified by the binding of drug with the receptor. For instance, Receptors might be available on
neurons in the CNS to reduce pain sensation (Weerink et al., 2017).
Ans. 4
First-pass effect is when a drug administered to the patient, enters his or her liver and goes
through widespread biotransformation and therefore reducing the concentration quickly before it
reaches to its target (Kamath, 2016). It takes place most usually when a drug is provided orally.
Later the drug is absorbed in patient’s GIT and reaches the portal circulation beforehand entering
patient’s systemic circulation (Wang, et al., 2017). Through the portal flow it transports to the
liver where certain drugs undertake widespread biotransformation and the concentration of the

SAM
4
drug is reduced (Svennebring, 2015). Therefore it is the portion of lost medicine throughout the
course of absorption commonly associated with the liver (Tian et al., 2016).
Ans. 5
A) Glyceryl Trinitrate 600 microgram is designed to liquefy rapidly underneath the tongue.
This particular area of the human mouth has a great supply of the blood vessels that
permits the drug to be quickly absorbed (Abbas, Elsherbini & Shaldam, 2019). Glyceryl
Trinitrate 600 microgram administered in this manner is used to provide quick release
from the pain of associated with angina attack. Patients are recommended to not to
swallow, suck or chew the medicine like other drugs (Thompson, A. (2016).
B)
 The patient must be educated about placing the medicine beneath the tongue only
 Ms. Scott should be informed to keep the drug with her always in case she needs to
take one.
 They must contact to the health professional like nurses if experience any side effect
after taking this drug and must avoid consuming alcohol as it can enhance the side
effects of this drug like feeling faintness, or dizziness (Scutt et al., 2018).
 the dosage must be repeated after 5 minutes if the symptoms are not resolved
 It is best to advice Ms. Scott to sit down before when taking the medicine as
otherwise it might make her feel dizzy (Omar, Jasudass & Saad, 2015).

SAM
5
Ans. 6
 The main role of doctors is to prescribe the drug according to the healthcare needs of the
patient (Liu, Gerdtz, & Manias, 2016).
 They undertake the patient consultation and perform physical examination before
prescribing the drug
 They make the complex decision related to the administration of the drug (McGavock,
2017).
Role of RN
 They must assess the patient for any allergies associated with any content of the drug
 They educate the patient and their family about the do’s and don’ts of the drug
 They must also ensure the five rights of medication administration (Venables & Gunnell,
2018).
Pharmacist
 They read the prescription of the doctor and provide the right drug to the patient so that
medication error can be avoided
 They educate the patient about safe storage of the drug
 They can also inform the patient and their family about drug interaction associated with
the particular drug (McGavock, 2017).

SAM
6
Ans. 7
Medication management cycle
1. Decision to treat and prescribe: the prescriber should assess to the accurate, complete
and updated consumer related information and include the patient in the decision making
process
2. Record of the medicine order/prescription: the information of the prescription must be
recorded to transfer to other person in the chain. There should be a proper communication
between patient, nurses, and pharmacist, and physician (Lindblad, Flink & Ekstedt,
2017).
3. Review of the medication order/prescription: review provides important safety for the
patient, it ensures the compliance with the requirement of legislation, optimal medicinal
use, verify intentions, and administration.
4. Issue of medicine: issuing a drug involves the processes of dispensing, developing, or
transferring, and is commonly undertaken by the pharmacist or the endorsed nurses. The
exact medicine should be developed or selected, labelled completely and clearly, and a
record of an issue made.
5. Provision of the medicine information: Provision of patient -specific drug information,
counting how to stock and correctly use medications, and improves safety (Coffman,
Vanderveen, Lee & Schlotterbeck, 2017).
6. Distribution and storage: once issued, the medicines are supplied to the care delivery
areas like ward within the health care facility.
7. Administration of the medicine: this particular step includes the reassessment of need,
choice of exact medicine, preparation and administration for the right person every time.

SAM
7
8. Monitor for the response: the health professional receive the medicine associated
response of the consumer to identify the efficacy and side effects of the drug to the
particular patient (Neyarapally & Smith, 2017).
9. Transfer of verified information: information on the drug and related treatment plan is
essential to examine effectiveness, assist with the upcoming decision about the treatment,
and enable the safe transfer of patient care, particularly when other healthcare
professional is involved in the current patient care. This involves the present medicine
regimen, quantity of the drug, and change of the treatment during the patient care
episodes (Blanchard et al., 2016).
Causes of medication error
1. High staff workload and fatigue can leads to wrong prescription and treatment
2. Lack of effective communication between the team members and patient
3. In-experienced and inadequately trained healthcare staff can also impacts the safe
administration of the drug and leads to medicinal error
4. Confusion in the nomenclature, packaging, and labelling of the drug
5. Lack of effective policies and procedures associated with the drugs
6. Increased number or the quantity of medicines per patient (Neyarapally & Smith, 2017).
7. Environmental factor like poor lighting, extra noise, frequent interruptions, and lack of
facilities for proper communication with the patient.
8. Frequency and the complexity of the calculation required to prescribe, distribute or
administer the medicines (Coffman, Vanderveen, Lee & Schlotterbeck, 2017).

SAM
8
Ans. 8
A)

SAM
9
Person centered approach System approach
This approach focuses on the human individual
as the sole source of the unsafe act (Paciello,et
al., 2016)
This approach focuses on the common
assumption that the humans are fallible and the
errors can be expected
Humans commit different errors because of
aberrant psychological process, For example;
 Physiological and the biological aspects
like stress or tiredness
 Information and skill-based aspects like
lack of experience and inappropriate
training
 Common information processing
shortages like selective attention or
omission (World Health Organization,
2016).
errors as the consequences instead of causes
Concentrate on the factors that affect errors
Complexity of the modern socio-technological
systems as the error source
Explanation of the unsafe action and
developing through;
 working environment such as working
availability
 team factors such as communication
flow
 work-associated factors such as
obtainability of the materials and
resources (Spurgeon, Sujan, Cross &
Flanagan, 2019)
Elimination of other different situational
aspects
Unsafe actions are the specific responsibility
Typical related counter measures Typical related counter measures
Naming, blaming, shaming Enhance conditions of work
Change the behavior y training ( in order to
reduce the unwanted variability in behavior of
Install or enhance the health and safety of the
patient

SAM
10
health care professionals and patients
Removes and exchange individuals Change the Material mindset and culture of the
individual or patient
The person approach leftovers the leading
custom in medicine, as to a different place.
From selected viewpoints it has much to praise
it. Blaming persons is emotionally additional
satisfying than pointing institutions.
Individuals are observed as free mediators
capable of selecting between harmless and
unsafe styles of behaviour (Gilbert & Kim,
2018).
Latent disappointments, or errors at the “blunt
end” associated with the system be motivated
to be less obvious, and they are accredited to
wider organizational effects counting but not
restricted to economic restraints, quality
management scheme, structural culture,
distribution of resources, communication, work
procedures, administrative rules, guidelines,
etc. (Newton, Asimakopoulou, Al-Haboubi &
Scambler, 2017).
B) Defences, safeguards, and barriers are the finest ways to stop errors in a healthcare
facility. Every barrier is seen as the slice portion of cheese. In the perfect word, there are
no holes in the barriers. Though, in the actual world, the numerous defences arrange like
slices of the Swiss cheese model. When all the holes arrange in a line, system failure or
error might occur. The barriers can put in place, at the organization level, to prevent the
adverse events. For example two medicines with similar pronunciation can cause
confusion until safeguards are in place to prevent it. Without the safeguards or timely
interventions, for example cascades can compromise the patient safety (Stein & Heiss,
2015).

SAM
11
C) Both the latent conditions and active failures interrelate, making a window for the error
to occur. Latent conditions set the stage for the medicinal error, whereas active failures
incline to be the promoter for the medicinal.
1. Active failures
 use of incorrect procedures
 not following procedures
 not finishing a final system check correctly
2. Latent failures are caused by circumstances such as
 scheduling problems
 inadequate training,
 Lack of resources (Seshia et al., 2018).
Ans. 9
Factors to contribute medicinal error
1. High workload
2. In-experienced staff
3. Confusion with similar name medicines
4. Shift work
5. Environmental factors
High workload: nurses and other health care professional have to perform many tasks
daily and lack of staff in the healthcare facility can put the high workload pressure on available
staff as they have to perform additional tasks, this can ultimately leads to medicinal error. This

SAM
12
can be addressed by proper management activities like recruiting new staff members so that the
all health professional can focus on their actual work (Makary & Daniel, 2016).
In-experienced staff might not be able to administer drugs effectively and may effective
skills. This can be dealt with providing training to them and support for the senior staff (Dong,
Song, Chen & Zhen, 2017).
Night shifts can cause mental issues among healthcare professional such as stress,
depression, lack of sleep etc. this will directly cause medical errors. It can be reduced by
performing daily exercises helpful in reducing sleeping issues and consuming healthy diet
(Bogner, 2018).
Environmental error like poor lighting, additional noise, and interruption can be avoided
with proper management activities like high quality lighting, reducing the interruption while
administrating or prescribing drugs, and maintaining peaceful environment (Saini, et al., 2017).

SAM
13
References
Abbas, H. A., Elsherbini, A. M., & Shaldam, M. A. (2019). Glyceryl trinitrate blocks
staphyloxanthin and biofilm formation in Staphylococcus aureus. African health
sciences, 19(1), 1376-1384.
Blanchard, C., Livet, M., Ward, C., Sorge, L., Sorensen, T. D., & McClurg, M. R. (2017). The
active implementation frameworks: a roadmap for advancing implementation of
comprehensive medication management in primary care. Research in Social and
Administrative Pharmacy, 13(5), 922-929.
Bogner, M. S. (2018). Human Error in Medicine: A Frontier for Change 1. In Human error in
medicine (pp. 373-383). CRC Press.
Coffman, D. J., Vanderveen, T. W., Lee, B. A., & Schlotterbeck, D. L. (2017). U.S. Patent No.
9,600,633. Washington, DC: U.S. Patent and Trademark Office.
Department of Health: Therapeutic Goods administration (2019). Regulation impact statement:
Premarket assessment requirements for Australian manufactured medical devices.
Retrieved from: https://www.tga.gov.au/book/background-1
Dong, D., Song, F., Chen, N., & Zhen, J. (2017). Application and Practice of Risk Managements
Analysis Methods in Medication Error Prevention in Medi-cal Institutions. China
Pharmacist, 20(12), 2238-2241.

SAM
14
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015).
Introduction to clinical trials. In Fundamentals of clinical trials (pp. 1-23). Springer,
Cham.
Ghosh, D., Skinner, M., & Ferguson, L. R. (2006). The role of the Therapeutic Goods
Administration and the Medicine and Medical Devices Safety Authority in evaluating
complementary and alternative medicines in Australia and New
Zealand. Toxicology, 221(1), 88-94.
Gilbert, J., & Kim, J. A. (2018). To err is human: medication patient safety in aged care, a case
study. Quality in Ageing and Older Adults, 19(2), 126-134.
Kamath, A. V. (2016). Translational pharmacokinetics and pharmacodynamics of monoclonal
antibodies. Drug Discovery Today: Technologies, 21, 75-83.
Kulkarni, J. (2017). Pharmacogenomics in psychiatry–Clinical innovation utilised by the
Therapeutic Goods Administration and Food and Drug Administration. Australian & New
Zealand Journal of Psychiatry, 51(1), 93-94.
Kumari, B. S., Hanuja, G. S., Nagabhushanam, M. V., Reddy, D. N., & Bonthagarala, B. (2016).
Current Regulatory Requirements for Registration of Medicines, Compilation and
Submission of Dossier in Australian Therapeutic goods Administration. International
Journal of Advanced Scientific and Technical Research, ISSN, 2249-9954.
Lindblad, M., Flink, M., & Ekstedt, M. (2017). Safe medication management in specialized
home healthcare-an observational study. BMC health services research, 17(1), 598.

SAM
15
Liu, W., Gerdtz, M., & Manias, E. (2016). Creating opportunities for interdisciplinary
collaboration and patient‐centred care: how nurses, doctors, pharmacists and patients use
communication strategies when managing medications in an acute hospital
setting. Journal of clinical nursing, 25(19-20), 2943-2957.
Makary, M. A., & Daniel, M. (2016). Medical error—the third leading cause of death in the
US. Bmj, 353, i2139.
McGavock, H. (2017). How Drugs Work: Basic Pharmacology for Health Professionals. CRC
Press.
Newton, P., Asimakopoulou, K., Al-Haboubi, M., & Scambler, S. (2017). The case for a whole-
system approach. International Handbook of Positive Aging.
Neyarapally, G. A., & Smith, M. A. (2017). Variability in state Medicaid medication
management initiatives. Research in Social and Administrative Pharmacy, 13(1), 214-
223.
Omar, W. A. W., Jasudass, S. R. J., & Saad, S. R. M. (2015). Patient’s Knowledge and Use of
Sublingual Glyceryl Trinitrate Therapy in Taiping Hospital, Malaysia. Malay, 55, 57-3.
Paciello, M., Ghezzi, V., Tramontano, C., Barbaranelli, C., & Fida, R. (2016). Self-efficacy
configurations and wellbeing in the academic context: A person-centred
approach. Personality and Individual Differences, 99, 16-21.
Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L.
V., ... & Wason, J. M. (2018). Adaptive designs in clinical trials: why use them, and how
to run and report them. BMC medicine, 16(1), 29.

SAM
16
Piantadosi, S. (2017). Clinical trials: a methodologic perspective. John Wiley & Sons.
Saini, V., Garcia-Armesto, S., Klemperer, D., Paris, V., Elshaug, A. G., Brownlee, S., & Fisher,
E. S. (2017). Drivers of poor medical care. The Lancet, 390(10090), 178-190.
Scutt, P., Dixon, M., Appleton, J. P., Howard, H., Havard, D., Woodhouse, L. J., & Bath, P. M.
(2018). Consent procedures and relationship with outcome in the Rapid Intervention with
Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2).
Seshia, S. S., Bryan Young, G., Makhinson, M., Smith, P. A., Stobart, K., & Croskerry, P.
(2018). Gating the holes in the Swiss cheese (part I): E xpanding professor Reason's
model for patient safety. Journal of evaluation in clinical practice, 24(1), 187-197.
Sime, F. B., Stuart, J., Butler, J., Starr, T., Wallis, S. C., Pandey, S., ... & Roberts, J. A. (2018).
Pharmacokinetics of intravenous posaconazole in critically ill patients. Antimicrobial
agents and chemotherapy, 62(6), e00242-18.
Spurgeon, P., Sujan, M. A., Cross, S., & Flanagan, H. (2019). Human Factors and Systems
Approach to Patient Safety. In Building Safer Healthcare Systems (pp. 31-43). Springer,
Cham.
Stein, J. E., & Heiss, K. (2015, December). The Swiss cheese model of adverse event occurrence
—closing the holes. In Seminars in pediatric surgery (Vol. 24, No. 6, pp. 278-282). WB
Saunders.
Svennebring, A. M. (2015). Investigation of the prerequisites for the optimization of specific
plasma protein binding as a strategy for the reduction of first-pass hepatic
metabolism. Xenobiotica, 45(4), 286-301.

SAM
17
Thompson, A. (2016). Counselling in practice: Glyceryl trinitrate for acute angina. Australian
Pharmacist, 35(1), 46.
Tian, X., Gao, Y., Xu, Z., Lian, S., Ma, Y., Guo, X., & Huang, C. (2016). Pharmacokinetics of
mangiferin and its metabolite—Norathyriol, Part 1: Systemic evaluation of hepatic first‐
pass effect in vitro and in vivo. Biofactors, 42(5), 533-544.
Venables, R. H., & Gunnell, K. A. (2018). A Practical Guide to Medicine Administration.
Routledge.
Wagner, J. G. (2018). Pharmacokinetics for the pharmaceutical scientist. Routledge.
Wang, X., Zheng, M., Liu, J., Huang, Z., Bai, Y., Ren, Z., ... & Feng, F. (2017). Differences of
first-pass effect in the liver and intestine contribute to the stereoselective
pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. Journal of
ethnopharmacology, 209, 175-183.
Weerink, M. A., Struys, M. M., Hannivoort, L. N., Barends, C. R., Absalom, A. R., & Colin, P.
(2017). Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clinical
pharmacokinetics, 56(8), 893-913.
World Health Organization. (2016). Medication errors. Retrieved from:
https://apps.who.int/iris/bitstream/handle/10665/252274/9789241511643-eng.pdf
Wright, B. (2017). Clinical Trial Phases. In A Comprehensive and Practical Guide to Clinical
Trials (pp. 11-15). Academic Press.

SAM
18